A Phase I/II Trial Using Weekly Mitoxantrone Chemotherapy and G-CSF for the Treatment of Metastatic Hormone Refractory Prostate Cancer
OBJECTIVES: I. Study the effectiveness of mitoxantrone in patients with metastatic, hormone
refractory prostate cancer. II. Assess the side effects of mitoxantrone in this patient
population. III. Determine whether filgrastim (granulocyte colony-stimulating factor; G-CSF)
treatment can overcome chronic bone marrow suppression and facilitate a dose intensive
mitoxantrone chemotherapy regimen in this patient population.
OUTLINE: This is a dose escalation study. Patients receive a 30 minute intravenous infusion
of mitoxantrone once a week on day 1. On days 2-6 of each week, patients receive
subcutaneous filgrastim (granulocyte colony-stimulating factor; G-CSF). Treatment continues
for patients who respond to therapy and exhibit no disease progression. Dose escalation
proceeds until the maximum tolerated dose (MTD) of mitoxantrone with G-CSF support is
determined. The MTD is defined as the dose preceding that at which 2 or more patients
experience dose limiting toxicity. After the MTD is determined, an additional 20-40 patients
are enrolled at this dose level to examine their response to this therapy.
PROJECTED ACCRUAL: Approximately 12-24 patients will be accrued for the phase I portion of
this protocol. An additional 20-40 patients may be accrued for the phase II portion of this
Primary Purpose: Treatment
Raj Sadasivan, MD, PhD
Hope Cancer Institute, Inc.
United States: Federal Government
|Bethany Medical Center||Kansas City, Kansas 66102|
|Heartland Cancer Research and Treatment Center||Kansas City, Kansas 66106|